Genenta Science SpA ADR

Genenta Science SpA ADR EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genenta Science SpA ADR (GNTA) as of Oct 31, 2026 is -7.11 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -11.43 M USD — a change of -37.81% (higher).

EBITDA

-7.11 MUSD

YoY

-37.81%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genenta Science SpA ADR is 2025 -7.11 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genenta Science SpA ADR was 2024 -11.43 M USD. It decreases by -37.81% higher compared to the previous year.

The Genenta Science SpA ADR EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-5.11 M USD
Jan 1, 2020
-5.83 M USD
Jan 1, 2021
-6.65 M USD
Jan 1, 2022
-12.09 M USD
Jan 1, 2023
-12.92 M USD
Jan 1, 2024
-11.43 M USD
Jan 1, 2025
-7.11 M USD
The Genenta Science SpA ADR EBITDA history
YEAREBITDAYoY
-7.11 MUSD-37.81%
-11.43 MUSD-11.51%
-12.92 MUSD+6.87%
-12.09 MUSD+81.93%
-6.65 MUSD+13.97%
-5.83 MUSD+14.11%
-5.11 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genenta Science SpA ADR Stock analysis

What does Genenta Science SpA ADR do? Genenta Science S.p.A. generates value by developing hematopoietic stem cell gene therapies for solid tumors in Italy. The company focuses on its product Temferon, which is currently in Phase 1/2a clinical trials for the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. Additionally, the firm is expanding the application of Temferon to other solid tumor indications. The business model relies on a proprietary biologic platform designed to deliver immunomodulatory molecules directly to tumors by infiltrating monocytes and macrophages. As a clinical-stage biotechnology company incorporated in 2014 and headquartered in Milan, Italy, Genenta Science S.p.A. utilizes this platform to advance its therapeutic pipeline and address unmet medical needs in oncology. Genenta Science SpA ADR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genenta Science SpA ADR stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genenta Science SpA ADR is -7.11 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genenta Science SpA ADR changed from -11.43 M USD to -7.11 M USD, representing a -37.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Genenta Science SpA ADR since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Genenta Science SpA ADR historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Genenta Science SpA ADR

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Genenta Science SpA ADR